# Standard of Care Comparative Arm of Phase 1/2 Gene Therapy Trial DREPAMIR" in Severe Sickle Cell Disease Patients

> **NCT07752043** · NA · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 30 (estimated)

## Conditions studied

- Sickle Cell Disease (SCD)
- Vaso-occlusive Events

## Interventions

- **DRUG:** standard of care

## Key facts

- **NCT ID:** NCT07752043
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2030-03
- **Final completion:** 2030-03
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2026-08-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07752043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07752043, "Standard of Care Comparative Arm of Phase 1/2 Gene Therapy Trial DREPAMIR" in Severe Sickle Cell Disease Patients". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07752043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*